Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials

To evaluate 26 weeks of liraglutide treatment in type 1 diabetes (T1D) by subgroups in the ADJUNCT ONE and ADJUNCT TWO trials.

[1]  M. Nauck,et al.  GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art , 2020, Molecular metabolism.

[2]  P. Dandona,et al.  Adjunct therapies in treatment of type 1 diabetes , 2020, Journal of diabetes.

[3]  P. Dandona,et al.  Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26‐week randomized controlled trial; mechanisms of weight loss , 2020, Diabetes, obesity & metabolism.

[4]  Deepak L. Bhatt,et al.  The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials , 2020, Diabetes, obesity & metabolism.

[5]  D. Michael,et al.  Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: A systematic review and meta-analysis. , 2020, Current diabetes reviews.

[6]  M. Redondo,et al.  Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents , 2020, Diabetes Care.

[7]  R. Pratley,et al.  Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme , 2020, Diabetes, obesity & metabolism.

[8]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[9]  K. Nørgaard,et al.  Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial , 2019, Diabetes, obesity & metabolism.

[10]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[11]  K. Tuttle,et al.  233-OR: Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) vs. Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria Status: AWARD-7 , 2019, Diabetes.

[12]  P. Dandona,et al.  Addition of glucagon‐like peptide‐1 receptor agonist therapy to insulin in C‐peptide‐positive patients with type 1 diabetes , 2019, Diabetes, obesity & metabolism.

[13]  N. Sattar,et al.  Excess Cardiovascular Risk in Type 1 Diabetes Mellitus: Role for a Dysfunctional Immune Response? , 2019, Circulation.

[14]  M. Phillip,et al.  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study , 2018, Diabetes Care.

[15]  B. Zinman,et al.  Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials , 2018, Diabetes Care.

[16]  A. Hattersley,et al.  Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study , 2018, The Lancet.

[17]  C. Mathieu,et al.  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial , 2018, Diabetes Care.

[18]  P. Lapuerta,et al.  Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study , 2018, Diabetes Care.

[19]  V. Aroda.  A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials , 2018, Diabetes, obesity & metabolism.

[20]  D. Nathan,et al.  The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study , 2017, Diabetologia.

[21]  P. Lapuerta,et al.  Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes , 2017, The New England journal of medicine.

[22]  P. Yu,et al.  Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2017, Diabetes Therapy.

[23]  Björn Eliasson,et al.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.

[24]  R. Beck,et al.  Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries. , 2016, Diabetes research and clinical practice.

[25]  J. Blundell,et al.  Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity , 2017, Diabetes, obesity & metabolism.

[26]  B. Zinman,et al.  Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial , 2016, Diabetes Care.

[27]  I. Hirsch,et al.  Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial , 2016, Diabetes Care.

[28]  J. Holst,et al.  Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[29]  R. Henry,et al.  Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes , 2015, Diabetes Care.

[30]  J. Holst,et al.  Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study , 2015, Diabetes Care.

[31]  N. Sattar,et al.  Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? , 2013, Diabetologia.

[32]  Simon R. Heller,et al.  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.

[33]  I. D. de Boer.  Liraglutide and Renal Outcomes in Type 2 Diabetes. , 2017, The New England journal of medicine.